William Blair Has Pessimistic Outlook of PRCT Q1 Earnings

PROCEPT BioRobotics Co. (NASDAQ:PRCT) – Equities researchers at William Blair decreased their Q1 2025 earnings per share estimates for shares of PROCEPT BioRobotics in a report released on Tuesday, February 25th. William Blair analyst B. Vazquez now expects that the company will earn ($0.48) per share for the quarter, down from their previous forecast of ($0.38). The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.75) per share. William Blair also issued estimates for PROCEPT BioRobotics’ Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.50) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.94) EPS.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The business had revenue of $68.24 million for the quarter, compared to analyst estimates of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%.

PRCT has been the subject of several other reports. Jefferies Financial Group initiated coverage on PROCEPT BioRobotics in a research note on Thursday, November 14th. They set a “hold” rating and a $95.00 target price for the company. Morgan Stanley dropped their target price on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a report on Wednesday. Wells Fargo & Company restated an “overweight” rating and issued a $112.00 target price on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. Finally, Truist Financial restated a “buy” rating and issued a $90.00 target price (down from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $94.29.

PROCEPT BioRobotics Trading Down 1.0 %

Shares of PRCT stock opened at $64.34 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. The company has a market cap of $3.36 billion, a price-to-earnings ratio of -32.99 and a beta of 1.03. The stock has a 50 day simple moving average of $74.93 and a 200-day simple moving average of $79.84. PROCEPT BioRobotics has a 1-year low of $45.56 and a 1-year high of $103.81.

Insider Activity

In related news, EVP Alaleh Nouri sold 28,092 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $97.13, for a total transaction of $2,728,575.96. Following the transaction, the executive vice president now owns 52,472 shares of the company’s stock, valued at approximately $5,096,605.36. This represents a 34.87 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Reza Zadno sold 26,423 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $97.22, for a total value of $2,568,844.06. Following the transaction, the chief executive officer now directly owns 152,762 shares in the company, valued at approximately $14,851,521.64. The trade was a 14.75 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 17.40% of the company’s stock.

Hedge Funds Weigh In On PROCEPT BioRobotics

Hedge funds have recently bought and sold shares of the company. Raleigh Capital Management Inc. acquired a new position in PROCEPT BioRobotics during the 4th quarter worth about $32,000. Thematics Asset Management acquired a new stake in PROCEPT BioRobotics in the 4th quarter valued at about $46,000. Signaturefd LLC raised its position in PROCEPT BioRobotics by 26.7% in the 4th quarter. Signaturefd LLC now owns 689 shares of the company’s stock valued at $55,000 after purchasing an additional 145 shares in the last quarter. IFP Advisors Inc acquired a new stake in PROCEPT BioRobotics in the 4th quarter valued at about $58,000. Finally, Arcadia Investment Management Corp MI acquired a new stake in PROCEPT BioRobotics in the 4th quarter valued at about $64,000. Institutional investors and hedge funds own 89.46% of the company’s stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).